Haloperidol lactate - Generic Drug Details

What are the generic sources for haloperidol lactate and what is the scope of freedom to operate?

Haloperidol lactate is the generic ingredient in four branded drugs marketed by Ortho Mcneil, Alpharma, Lannett Co Inc, Morton Grove, Pharm Assoc, Rubicon Research, SCS, Teva, Teva Pharms, Hikma, Janssen Pharms, Abraxis Pharm, Baxter Hlthcare Corp, Epic Pharma Llc, Fosun Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Smith And Nephew, Solopak, Teva Pharms Usa, Watson Labs, and Actavis Mid Atlantic, and is included in thirty-four NDAs. Additional information is available in the individual branded drug profile pages.

Twelve suppliers are listed for this compound.

Summary for haloperidol lactate

US Patents:	0
Tradenames:	4
Applicants:	25
NDAs:	34
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	5
Patent Applications:	618
What excipients (inactive ingredients) are in haloperidol lactate?	haloperidol lactate excipients list
DailyMed Link:	haloperidol lactate at DailyMed

See drug sales revenues for haloperidol lactate

Recent Clinical Trials for haloperidol lactate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Christian Hassager	Phase 3
Services Institute of Medical Sciences, Pakistan	Phase 1
University Hospital, Basel, Switzerland	Phase 4

See all haloperidol lactate clinical trials

Pharmacology for haloperidol lactate

Drug Class

Typical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for haloperidol lactate

N05AD	Butyrophenone derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for haloperidol lactate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Marsam Pharms Llc	HALOPERIDOL	haloperidol lactate	INJECTABLE;INJECTION	072516-001	Feb 25, 1993		DISCN	No	No
Fresenius Kabi Usa	HALOPERIDOL	haloperidol lactate	INJECTABLE;INJECTION	075689-001	Mar 9, 2001	AP	RX	No	No
Watson Labs	HALOPERIDOL	haloperidol lactate	INJECTABLE;INJECTION	070744-001	May 17, 1988		DISCN	No	No

Expired US Patents for haloperidol lactate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ortho Mcneil	HALDOL	haloperidol lactate	CONCENTRATE;ORAL	015922-001	Approved Prior to Jan 1, 1982
Janssen Pharms	HALDOL	haloperidol lactate	INJECTABLE;INJECTION	015923-001	Approved Prior to Jan 1, 1982

Market Dynamics and Financial Trajectory for Haloperidol Lactate

Last updated: February 20, 2026

What is the current market landscape for haloperidol lactate?

Haloperidol lactate is an antipsychotic medication used primarily for managing schizophrenia, acute psychosis, and Tourette’s syndrome. It is available in injection form and administered in hospital and clinic settings. The global market for haloperidol variants, including haloperidol lactate, is driven by the prevalence of psychiatric disorders and the long-standing use of first-generation antipsychotics.

The drug's commercial presence includes branded formulations like Haldol (Johnson & Johnson) and various generic equivalents. Market penetration is highest in North America and Europe, where healthcare infrastructure supports antipsychotic treatments. Emerging markets demonstrate increasing adoption, driven by expanding mental health awareness and growing healthcare infrastructure.

How has the demand for haloperidol lactate evolved?

Demand trends reflect the broader decline in first-generation antipsychotic use for some indications, replaced by second-generation drugs with fewer side effects. Nevertheless, haloperidol lactate remains in use because of its affordability, availability, and long history of efficacy.

The global antipsychotic drug market was valued at approximately USD 11.4 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% through 2030. Haloperidol's market share within this segment is declining slightly due to competition from atypical antipsychotics, yet remains significant in hospital settings and for specific indications.

In 2020, data indicates a steady use of haloperidol in hospital settings, with prescriptions mainly in the United States accounting for approximately 40% of total use among antipsychotics. The demand variation is influenced by regulatory policies, availability of generics, and clinical guidelines.

What are the key drivers shaping the market?

1. Prevalence of Psychiatric Disorders

   • Global prevalence of schizophrenia is about 20 million people.
   • Rising awareness increases diagnosis rates.

2. Healthcare Infrastructure and Access

   • Expansion in emerging economies broadens treatment access.
   • Hospital-based administration supports injectable formulations.

3. Cost and Reimbursement Policies

   • Lower-cost generics maintain market share amid expensive newer drugs.
   • Reimbursement policies favor hospital-administered drugs.

4. Clinical Guidelines

   • Continuing endorsement for haloperidol in acute settings.
   • Shift towards second-generation antipsychotics reduces outpatient prescriptions.

5. Regulatory Factors

   • Regulatory approvals maintain patent-free access.
   • Labeling updates influence prescribing practices.

How do competitive forces impact the financial trajectory?

Generic Competition: Most formulations, including haloperidol lactate, are off-patent, leading to intense price competition. Wholesale prices for generics typically range from USD 0.02 to 0.10 per dose, a significant reduction compared to branded formulations.

Market Entry of New Drugs: While newer atypical antipsychotics like risperidone and olanzapine dominate outpatient markets, haloperidol remains relevant in inpatient and emergency scenarios given its low cost and proven efficacy.

Supply Chain and Manufacturing: Multiple manufacturers produce haloperidol lactate, ensuring supply stability. Minor price variations occur based on manufacturer capacity and regulatory compliance costs.

Regulatory Influences: Countries with strict regulatory environments have delineated formulations and approved biosimilars, affecting pricing strategies.

What are the financial projections?

Market Size and Revenue

Year	Estimated Global Sales (USD billion)	Growth Rate	Major Market Share (USD billion)
2022	0.45	2%	North America (50%), Europe (20%)
2025	0.55	3.5% CAGR	U.S. (50%), Europe (20%)
2030	0.68	3.5% CAGR	North America (52%), Europe (18%)

Segment Breakdown: Hospitals account for 75% of use, with consistent demand driven by inpatient care, especially in acute psychoses and emergency settings.

Pricing Trends: Generic prices are decreasing, but volume sustains revenues. The average wholesale price in 2022 ranges from USD 0.04 to 0.10 per injection, depending on the supplier and regional pricing policies.

Investment Outlook: The market remains stable due to ongoing demand in inpatient settings and long-standing manufacturing infrastructure. Significant growth is unlikely; however, steady revenue is projected for the next five years, driven by hospital acquisitions and global mental health initiatives.

What regulatory factors influence market trajectory?

• FDA and EMA approvals for off-label use of haloperidol lactate sustain availability.
• Reclassification of some formulations as controlled substances in select jurisdictions impacts distribution.
• Quality standards influence production costs and international trade.

Key Takeaways

• The global market for haloperidol lactate remains stable, with an estimated USD 0.45 billion in 2022.
• Demand is primarily driven by inpatient hospital use for acute psychiatric episodes.
• Price competition from generics drives low per-dose costs; revenues are volume-dependent.
• Market growth is modest, with a CAGR of approximately 3.5% until 2030.
• Market stability is supported by long-standing clinical protocols and healthcare infrastructure in developed regions.

FAQs

1. How does the generic status of haloperidol lactate influence its market?
The availability of multiple generic manufacturers results in intense price competition, keeping costs low and maintaining demand mainly due to volume.

2. Are there significant regional variations in demand?
Yes. North America leads in demand due to higher hospital-based treatment rates, while emerging markets are increasing use thanks to expanding healthcare infrastructure.

3. What is the primary use setting for haloperidol lactate?
It is predominantly used in hospital settings for acute psychosis, agitation, and severe psychiatric episodes.

4. How might regulatory changes impact the future market?
Tighter controls or reclassification could restrict access or alter prescribing practices, while approvals of biosimilars may further lower prices.

5. What are potential avenues for growth or decline?
Growth opportunities include increasing mental health diagnoses and expanded access in emerging markets; decline factors include shift toward second-generation antipsychotics for outpatient management.

References

[1] Market Research Future. (2022). Global antipsychotic drugs market report.
[2] IQVIA Institute. (2021). Medicine Use and Spending in the US: A Review of 2021 and Outlook for 2022.
[3] Grand View Research. (2022). Antipsychotic drugs market size, share, trends.
[4] U.S. Food & Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[5] European Medicines Agency. (2022). Product information for haloperidol.